摘要
目的探讨叉头框蛋白P1(FOXP1)与Livin基因表达对淋巴瘤临床病理特征及预后的评价价值。方法选择2013-08至2015-08间在我院肿瘤科住院治疗的弥漫性大B细胞淋巴瘤患者80例为观察组,40例反应性淋巴结增生患者为对照组,观察并分析两组FOXP1与Livin表达情况。分析淋巴瘤患者FOXP1、Livin表达与临床病理特征的关系。结果观察组FOXP1及Livin高表达的比例分别为77.5%、60.0%,均显著高于对照组比例20.0%、5.0%,差异具有统计学意义(P<0.05)。淋巴瘤患者中,高中危+高危IPI、原发部位(节内)、Non-GCB者FOXP1高表达比例分别为92.3%、86.2%、86.7%,比例更高,差异具有统计学意义(P<0.05),存在B症状、高中危+高危IPI、Non-GCB者Livin高表达的比例分别为81.2%、80.8%、73.3%,比例更高,差异具有统计学意义(P<0.05)。结论弥漫性大B细胞淋巴瘤内FOXP1及Livin表达水平与其临床特征、病理类型存在密切关系。
Objective To explore the significance of FOXP1 and Livin expressions in the evaluation of clinicopathological characteristics and prognosis of lymphoma. Methods Eighty patients with diffuse large B cell lymphoma treated at our hospital between August 2013 and August 2015 were selected as observation group,with 40 cases of reactive lymph node hyperplasia patients as control group. The expressions of FOXP1 and Livin in the two groups were observed and analyzed. The relationships between the expressions of FOXP1 and Livin in patients with lymphoma and the clinicopathological features were analyzed. Results The percentage of high expressions of FOXP1 and Livin in the observation group was 77. 5% and 60% respectively,which was significantly higher than that in the control group（ 20%,5%）,and the difference was statistically significant（ P〈0. 05）. Among the high-risk IPI and non-GCB patients of lymphoma or those with primary lymphoma,high expression rates of FOXP1 were 92. 3%,86. 2%,86. 7% respectively,the proportion was higher,and the difference was statistically significant（ P〈0. 05）. In the presence of B-symptom,the expression rates of Livin were 81. 2%,80. 8%,73. 3% respectively,the proportion was higher,and the difference was of statistic significance（ P〈0. 05）. Conclusions The expression level of FOXP1 and Livin in patients with diffuse large B cell lymphoma is closely related to its clinical features and pathological types.
作者
夏靖媛
徐薪
XIA Jingyuan XU Xin(Department of Pathology, General Hospital of Chinese People＇ s Armed Police Force, Beijing 100039, China)
出处
《武警医学》
CAS
2016年第12期1237-1240,共4页
Medical Journal of the Chinese People's Armed Police Force
